{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:18:12Z","timestamp":1771474692014,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T00:00:00Z","timestamp":1294358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study compared 1-year risk of psychiatric hospitalization and treatment costs in commercially insured patients with bipolar disorder, treated with aripiprazole, ziprasidone, olanzapine, quetiapine or risperidone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a retrospective propensity score-matched cohort study using the Ingenix Lab\/Rx integrated insurance claims dataset. Patients with bipolar disorder and 180 days of pre-index enrollment without antipsychotic exposure who received atypical antipsychotic agents were followed for up to 12 months following the initial antipsychotic prescription. The primary analysis used Cox proportional hazards regression to evaluate time-dependent risk of hospitalization, adjusting for age, sex and pre-index hospitalization. Generalized gamma regression compared post-index costs between treatment groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Compared to aripiprazole, ziprasidone, olanzapine and quetiapine had higher risks for hospitalization (hazard ratio 1.96, 1.55 and 1.56, respectively; p &lt; 0.05); risperidone had a numerically higher but not statistically different risk (hazard ratio 1.37; p = 0.10). Mental health treatment costs were significantly lower for aripiprazole compared with ziprasidone (p = 0.004) and quetiapine (p = 0.007), but not compared to olanzapine (p = 0.29) or risperidone (p = 0.80). Total healthcare costs were significantly lower for aripiprazole compared to quetiapine (p = 0.040) but not other comparators.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In commercially insured adults with bipolar disorder followed for 1 year after initiation of atypical antipsychotics, treatment with aripiprazole was associated with a lower risk of psychiatric hospitalization than ziprasidone, quetiapine, olanzapine and risperidone, although this did not reach significance with the latter. Aripiprazole was also associated with significantly lower total healthcare costs than quetiapine, but not the other comparators.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-244x-11-6","type":"journal-article","created":{"date-parts":[[2011,1,8]],"date-time":"2011-01-08T07:13:57Z","timestamp":1294470837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis"],"prefix":"10.1186","volume":"11","author":[{"given":"Edward","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quynh","family":"Van-Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,7]]},"reference":[{"issue":"10","key":"748_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1176\/ps.50.10.1303","volume":"50","author":"GE Simon","year":"1999","unstructured":"Simon GE, Unutzer J: Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 1999, 50 (10): 1303-1308.","journal-title":"Psychiatr Serv"},{"issue":"10","key":"748_CR2","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0149-2918(02)80070-4","volume":"24","author":"M Stender","year":"2002","unstructured":"Stender M, Bryant-Comstock L, Phillips S: Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther. 2002, 24 (10): 1668-1676. 10.1016\/S0149-2918(02)80070-4.","journal-title":"Clin Ther"},{"issue":"4","key":"748_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0165-0327(94)90104-X","volume":"31","author":"JD Lish","year":"1994","unstructured":"Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM: The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994, 31 (4): 281-294. 10.1016\/0165-0327(94)90104-X.","journal-title":"J Affect Disord"},{"issue":"1-3","key":"748_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0165-0327(01)00394-9","volume":"71","author":"J Li","year":"2002","unstructured":"Li J, McCombs JS, Stimmel GL: Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord. 2002, 71 (1-3): 131-139. 10.1016\/S0165-0327(01)00394-9.","journal-title":"J Affect Disord"},{"issue":"6","key":"748_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1176\/appi.ajp.159.6.1005","volume":"159","author":"C Blanco","year":"2002","unstructured":"Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA: Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry. 2002, 159 (6): 1005-1010. 10.1176\/appi.ajp.159.6.1005.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"748_CR6","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4088\/JCP.v67n0707","volume":"67","author":"JJ Guo","year":"2006","unstructured":"Guo JJ, Keck PE, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry. 2006, 67 (7): 1055-1061. 10.4088\/JCP.v67n0707.","journal-title":"J Clin Psychiatry"},{"issue":"4 Suppl","key":"748_CR7","first-page":"1","volume":"159","author":"APA","year":"2002","unstructured":"APA: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002, 159 (4 Suppl): 1-50.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"748_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/0269881103017002003","volume":"17","author":"GM Goodwin","year":"2003","unstructured":"Goodwin GM: Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003, 17 (2): 149-173. 10.1177\/0269881103017002003. discussion 147","journal-title":"J Psychopharmacol"},{"issue":"1","key":"748_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/15622970309167904","volume":"4","author":"H Grunze","year":"2003","unstructured":"Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ, Disorders WTFoTGfB: The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry. 2003, 4 (1): 5-13. 10.3109\/15622970309167904.","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"748_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.psc.2005.01.001","volume":"28","author":"LN Yatham","year":"2005","unstructured":"Yatham LN: Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am. 2005, 28 (2): 325-347. 10.1016\/j.psc.2005.01.001.","journal-title":"Psychiatr Clin North Am"},{"issue":"7","key":"748_CR11","doi-asserted-by":"publisher","first-page":"870","DOI":"10.4088\/JCP.v66n0710","volume":"66","author":"T Suppes","year":"2005","unstructured":"Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005, 66 (7): 870-886. 10.4088\/JCP.v66n0710.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"748_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1524-4733.2007.00287.x","volume":"11","author":"JJ Guo","year":"2008","unstructured":"Guo JJ, Keck PE, Li H, Jang R, Kelton CM: Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health. 2008, 11 (3): 416-423. 10.1111\/j.1524-4733.2007.00287.x.","journal-title":"Value Health"},{"issue":"4","key":"748_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.clinthera.2009.04.022","volume":"31","author":"E Kim","year":"2009","unstructured":"Kim E, Maclean R, Ammerman D, Jing Y, Pikalov A, You M, Van-Tran Q, L'Italien G: Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther. 2009, 31 (4): 836-848. 10.1016\/j.clinthera.2009.04.022.","journal-title":"Clin Ther"},{"issue":"2","key":"748_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3111\/13696990903044092","volume":"12","author":"Y Jing","year":"2009","unstructured":"Jing Y, Kim E, You M, Pikalov A, Tran QV: Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econom. 2009, 12 (2): 104-113. 10.3111\/13696990903044092.","journal-title":"J Med Econom"},{"issue":"3","key":"748_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","volume":"98","author":"RJ Glynn","year":"2006","unstructured":"Glynn RJ, Schneeweiss S, Sturmer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006, 98 (3): 253-259. 10.1111\/j.1742-7843.2006.pto_293.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"748_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992, 45 (6): 613-619. 10.1016\/0895-4356(92)90133-8.","journal-title":"J Clin Epidemiol"},{"key":"748_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev.publhealth.20.1.125","volume":"20","author":"P Diehr","year":"1999","unstructured":"Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY: Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999, 20: 125-144. 10.1146\/annurev.publhealth.20.1.125.","journal-title":"Annu Rev Public Health"},{"issue":"3","key":"748_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jhealeco.2004.09.011","volume":"24","author":"WG Manning","year":"2005","unstructured":"Manning WG, Basu A, Mullahy J: Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005, 24 (3): 465-488. 10.1016\/j.jhealeco.2004.09.011.","journal-title":"J Health Econ"},{"issue":"6","key":"748_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/YIC.0b013e32830b0f88","volume":"23","author":"FD Gianfrancesco","year":"2008","unstructured":"Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH: The association between treatment adherence and antipsychotic dose among individuals with bipolar disorder. Int Clin Psychopharmacol. 2008, 23 (6): 305-316. 10.1097\/YIC.0b013e32830b0f88.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1-3","key":"748_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.schres.2008.11.017","volume":"108","author":"L Citrome","year":"2009","unstructured":"Citrome L, Reist C, Palmer L, Montejano L, Lenhart G, Cuffel B, Harnett J, Sanders KN: Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res. 2009, 108 (1-3): 238-244. 10.1016\/j.schres.2008.11.017.","journal-title":"Schizophr Res"},{"issue":"2","key":"748_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4088\/JCP.v67n0208","volume":"67","author":"FD Gianfrancesco","year":"2006","unstructured":"Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH: Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry. 2006, 67 (2): 222-232. 10.4088\/JCP.v67n0208.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"748_CR22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18553\/jmcp.2004.10.1.48","volume":"10","author":"Z Wang","year":"2004","unstructured":"Wang Z, Salmon JW, Walton SM: Cost-effectiveness analysis and the formulary decision-making process. J Manag Care Pharm. 2004, 10 (1): 48-59.","journal-title":"J Manag Care Pharm"},{"key":"748_CR23","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511803161","volume-title":"Causality: Models, Reasoning and Inference","author":"J Pearl","year":"2009","unstructured":"Pearl J: Causality: Models, Reasoning and Inference. 2009, Cambridge University Press, 2","edition":"2"},{"key":"748_CR24","volume-title":"National Bureau of Economic Research Working paper 13934","author":"Heckman","year":"2008","unstructured":"Heckman : Econometric causality. National Bureau of Economic Research Working paper 13934. 2008"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-11-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-11-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T06:42:56Z","timestamp":1630478576000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-11-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-11-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,7]]},"assertion":[{"value":"30 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"6"}}